Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations
Cancer Res 61(18):66496655 Huang X et al (2010) Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
Use antibacterial mouthwash as prescribed by your dentist
2018 Jul 5;373(1750)
Peptides expected to return to legal compounding status include: BPC-157 - studied for tissue repair, gut healing, and inflammation reduction Thymosin Alpha-1 - an immune-modulating peptide used in infectious disease and oncology support TB-500 (Thymosin Beta-4) - studied for muscle repair, flexibility, and recovery CJC-1295 and Ipamorelin - growth hormone-releasing peptides supporting sleep, metabolism, and lean muscle AOD-9604 - a peptide fragment studied for fat metabolism Selank and Semax - neuropeptides studied for cognitive function and anxiety GHK-Cu - a copper peptide studied for wound healing and regeneration MOTS-C - a mitochondrial peptide studied for metabolic regulation Important: Category 1 reclassification is not the same as FDA approval
The effective patent life looks like this: This is a compressed illustration, but it captures the structure
